Skip to main content
. 2020 Apr 4;9(7):e015548. doi: 10.1161/JAHA.119.015548

Table 1.

Baseline Characteristics of the Study Population Stratified by the Presence of Preeclampsia at the Time of Demonstration of sFlt‐1/PlGF >655

Characteristics Total (N=237) Preeclampsia at Inclusion
No (n=52) Yes (n=185) P Value
Maternal age, y 33.7±5.8 32.0±6.1 31.6±5.8 0.49
Height, cm 161.1±9.1 162.2±7.3 159.7±8.5 0.09
Prepregnancy weight, kg 69.1±15.2 71.0±17.0 68.9±14.8 0.59
Prepregnancy BMI, kg/m2 26.7±6.4 26.5±6.0 26.6±6.0 0.96
Smoking status
Current 7 (3.0) 1 (1.9) 6 (3.3) 0.16
Cigarettes/d, median (range) 9 (3–20) 8 (3–24) 10 (4–20)
Race or ethnic groupb
White 169 (71.3) 42 (80.8) 127 (68.7)
Hispanic 35 (14.8) 7 (13.5) 28 (15.1)
Asian 5 (2.1) 0 (0) 5 (2.7) 0.60
Black 11 (4.6) 1 (1.9) 10 (5.4)
Arab 14 (5.9) 2 (3.8) 12 (6.5)
Other 3 (0.4) 0 (0) 3 (1.6)
Risk factors for PD
High
Previous preeclampsia 25 (10.5) 0 (0) 25 (13.5) 0.01
Chronic hypertension 30 (12.7) 4 (7.7) 26 (14.1) 0.22
Prepregnancy diabetes mellitus 1 (0.4) 0 (0) 1 (0.54) 0.60
Chronic kidney disease 4 (1.7) 0 (0) 4 (2.2) 0.49
Thrombophilia 5 (2.1) 1 (1.9) 4 (2.2) 0.92
Systemic lupus erythematosus 3 (1.3) 0 (0) 3 (1.6) 0.11
Moderate
Nulliparity 159 (67.1) 34 (65.4) 125 (67.6) 0.77
Age ≥40 y 13 (16.7) 3 (5.8) 10 (5.4) 0.92
Prepregnancy BMI ≥35 23 (10.0) 5 (9.6) 18 (9.7) 0.98
Family history of preeclampsiaa 7 (3.0) 0 (0) 7 (3.8) 0.35
≥1 High‐risk or 2 moderate‐risk factors 74 (31.2) 11 (21.2) 64 (34.6) 0.07
Mode of conception
Spontaneous 215 (90.7) 46 (88.5) 165 (89.2)
In vitro fertilization 16 (6.8) 6 (11.5) 10 (5.4) 0.06
Oocyte donation 6 (2.5) 0 (0) 6 (3.2)
Low‐dose aspirin intake (100 mg/d)
No 204 (86.4) 45 (86.5) 158 (85.4) 0.68
Starting at or before 16 wk 29 (12.3) 7 (13.5) 22 (11.9)
Starting after 16 wk 3 (1.3) 0 (0) 3 (1.6)
Low‐dose heparin prophylaxis
No 210 (88.6) 47 (90.4) 163 (88.1)
Starting at or before 16 wk 6 (2.5) 1 (1.9) 5 (2.7) 0.89
Starting after 16 wk 21 (8.9) 4 (7.7) 17 (9.2)

Data are mean±SD or n (%), unless otherwise stated. BMI indicates body mass index; PD, placental dysfunction; PlGF, placental growth factor; and sFlt‐1, soluble fms‐like tyrosine kinase 1.

a

First‐degree relative (mother or sister) with a history of preeclampsia.

b

Evaluated after Bonferroni adjustment.